Reversal of HIV-1-associated osteoporosis with once-weekly alendronate.
HIV-1-infected patients with osteoporosis were randomly assigned to alendronate 70 mg once-weekly plus dietary counselling (n = 11) or diet counselling alone (n = 14). At week 96, 27% of patients on alendronate versus 96% of controls presented with osteoporosis. Spine bone mineral density (BMD) increases were detected at week 48, and progressed thereafter. Improvements in trochanter BMD were obtained after 2 years. Once-weekly oral alendronate may be an effective and safe treatment for HIV-1-associated osteoporosis.
Negredo
Eugenia
E
Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Barcelona, Spain.
Martínez-López
Eva
E
Paredes
Roger
R
Rosales
Joaquim
J
Pérez-Alvarez
Núria
N
Holgado
Susana
S
Gel
Silvia
S
del Rio
Luís
L
Tena
Xavier
X
Rey-Joly
Celestino
C
Clotet
Bonaventura
B
D019386:Alendronate / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications*; D015497:HIV-1; D006801:Humans; D010024:Osteoporosis / Q000178:diet therapy / Q000188:drug therapy* / Q000821:virology; D010865:Pilot Projects
D019386:Alendronate